|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Millennium_Pharmaceuticals
gptkb:TetraLogic_Pharmaceuticals
gptkb:LigoCyte_Pharmaceuticals
gptkb:Alder_BioPharmaceuticals
gptkb:Apexigen
gptkb:Envoy_Therapeutics
gptkb:Shire_plc
gptkb:ArcherDX
gptkb:Talecris_Biotherapeutics
gptkb:Hepion_Pharmaceuticals
gptkb:Sierra_Oncology
Nycomed
TiGenix
Pioneer_Surgical_Technology
Zymeworks.
|
|
gptkbp:CEO
|
gptkb:Christophe_Weber
|
|
gptkbp:employees
|
50,000+
|
|
gptkbp:founded
|
1781
|
|
gptkbp:founder
|
gptkb:Chobei_Takeda_I
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda Pharmaceutical Company Limited
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market
|
$45 billion (2022)
|
|
gptkbp:partnerships
|
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
gptkb:AstraZeneca
gptkb:NantKwest
gptkb:Bristol-Myers_Squibb
gptkb:Novavax
gptkb:Pfizer
gptkb:Helsinn_Healthcare
gptkb:Amgen
Sanofi
|
|
gptkbp:products
|
Vaccines
Oncology drugs
Rare disease treatments
|
|
gptkbp:researchFocus
|
Gastroenterology
Immunology
Neurology
Hematology
Metabolic disorders
Cardiovascular
|
|
gptkbp:revenue
|
$30.5 billion (2022)
|
|
gptkbp:stockSymbol
|
4502 (TSE)
TAK_(NYSE)
|
|
gptkbp:subsidiary
|
gptkb:Takeda_Pharmaceuticals_International_AG
Takeda Pharmaceuticals USA, Inc.
|
|
gptkbp:website
|
www.takeda.com
|